Novavax, Inc. (NASDAQ:NVAX) Shares Bought by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. raised its holdings in Novavax, Inc. (NASDAQ:NVAX) by 262.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 43,573 shares of the biopharmaceutical company’s stock after acquiring an additional 31,559 shares during the period. Oppenheimer & Co. Inc.’s holdings in Novavax were worth $350,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Creative Planning grew its stake in shares of Novavax by 34.5% in the 3rd quarter. Creative Planning now owns 32,482 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 8,339 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Novavax in the 3rd quarter valued at approximately $214,000. US Bancorp DE boosted its position in shares of Novavax by 3,538.8% during the 3rd quarter. US Bancorp DE now owns 12,299 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 11,961 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Novavax during the 3rd quarter worth approximately $368,000. Finally, Entropy Technologies LP purchased a new position in shares of Novavax during the 3rd quarter worth approximately $158,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. TD Cowen raised shares of Novavax to a “hold” rating in a research report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th. Finally, BTIG Research assumed coverage on shares of Novavax in a research report on Friday, February 28th. They set a “buy” rating and a $19.00 price objective for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Novavax has an average rating of “Hold” and an average price target of $18.00.

Insider Activity at Novavax

In other news, Director James F. Young sold 5,400 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total value of $43,200.00. Following the transaction, the director now directly owns 51,760 shares in the company, valued at approximately $414,080. This trade represents a 9.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Rachel K. King sold 4,150 shares of the firm’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the transaction, the director now owns 14,770 shares in the company, valued at approximately $133,225.40. The trade was a 21.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 14,150 shares of company stock valued at $119,641. Corporate insiders own 1.00% of the company’s stock.

Novavax Price Performance

NVAX stock opened at $8.34 on Friday. The company’s 50 day simple moving average is $8.46 and its 200-day simple moving average is $9.81. The firm has a market capitalization of $1.34 billion, a PE ratio of -3.69, a P/E/G ratio of 2.85 and a beta of 2.92. Novavax, Inc. has a 12 month low of $3.81 and a 12 month high of $23.86.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to analysts’ expectations of $85.48 million. During the same period in the previous year, the company posted ($1.44) EPS. As a group, sell-side analysts anticipate that Novavax, Inc. will post -1.46 earnings per share for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.